Mycoplasma

Global Sexually Transmitted Diseases (STDs) Drug Market Research Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 11, 2021
Health, Pharmaceutical, Disease transmission, Mycoplasma, Sexually transmitted infection

The "Sexually Transmitted Diseases (STDs) Drug - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sexually Transmitted Diseases (STDs) Drug - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Sexually Transmitted Diseases (STDs) Drug estimated at US$47.7 Billion in the year 2020, is projected to reach a revised size of US$91.7 Billion by 2027, growing at a CAGR of 9.8% over the analysis period 2020-2027.
  • Chlamydia, one of the segments analyzed in the report, is projected to record a 10% CAGR and reach US$14.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $12.9 Billion, While China is Forecast to Grow at 13.1% CAGR
    The Sexually Transmitted Diseases (STDs) Drug market in the U.S. is estimated at US$12.9 Billion in the year 2020.

Cicero Diagnostics Introduces Fertility App for ReceptivaDx

Retrieved on: 
Tuesday, June 8, 2021
Women, Software, Health, Family, Technology, Consumer, Mobile, Wireless, Other Health, Fertility medicine, Infertility, Mycoplasma, Women's health, HERE WeGo, Software

Cicero Diagnostics Inc., a womens healthcare diagnostic company offering the ReceptivaDx test for unexplained infertility and recurrent pregnancy loss, today announced the availability of a new app for IOS and Android called ReceptivaDxTest.

Key Points: 
  • Cicero Diagnostics Inc., a womens healthcare diagnostic company offering the ReceptivaDx test for unexplained infertility and recurrent pregnancy loss, today announced the availability of a new app for IOS and Android called ReceptivaDxTest.
  • The app is an informational and educational tool designed to support women and physicians through their experience with the ReceptivaDx test.
  • View the full release here: https://www.businesswire.com/news/home/20210608005216/en/
    The ReceptivaDx app home screen presents two user options.
  • In-app resources allow women to schedule free consultations with Cicero Diagnostics or find local clinics that offer the test.

Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Retrieved on: 
Tuesday, June 1, 2021
Infectious causes of cancer, Chlamydiae, Sexually transmitted diseases and infections, Medical specialties, Pathogenic bacteria, Bacteria, Clinical medicine, Mycoplasma, Lactic acid/citric acid/potassium bitartrate, Sexually transmitted infection, Bitartrate, Chlamydia

Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).

Key Points: 
  • Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).
  • The Company launched its first FDA-approved commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), inthe United StatesinSeptember 2020.
  • The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD .'
  • Phexxiis a registered trademark of Evofem Biosciences, Inc.

INVO Bioscience to Report First Quarter 2021 Financial Results on Monday, May 17, 2021

Retrieved on: 
Tuesday, May 11, 2021
Women's health, Fertility medicine, Mycoplasma, Human reproduction, Infertility, Vagina, Branches of biology, Reproduction

b'SARASOTA, Fla., May 11, 2021 /PRNewswire/ --INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world\'s only in vivo Intravaginal Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its first quarter 2021, ended March 31, 2021, after the market close on Monday, May 17, 2021.

Key Points: 
  • b'SARASOTA, Fla., May 11, 2021 /PRNewswire/ --INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world\'s only in vivo Intravaginal Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its first quarter 2021, ended March 31, 2021, after the market close on Monday, May 17, 2021.
  • Our solution, the INVO Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.
  • Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART).
  • Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov .

Insights on the Sexually Transmitted Disease (STD) Testing Global Market to 2025 - The Presence of Favorable Reimbursement Policies is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Infectious diseases, Disease transmission, Mycoplasma, Sexually transmitted infection, STD

b'The "Global Sexually Transmitted Disease (STD) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe publisher has been monitoring the sexually transmitted disease (STD) testing market and it is poised to grow by $74.64 million during 2021-2025, progressing at a CAGR of over 8% during the forecast period.\nThe report on sexually transmitted disease (STD) testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\nThe report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • b'The "Global Sexually Transmitted Disease (STD) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe publisher has been monitoring the sexually transmitted disease (STD) testing market and it is poised to grow by $74.64 million during 2021-2025, progressing at a CAGR of over 8% during the forecast period.\nThe report on sexually transmitted disease (STD) testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\nThe report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • The market is driven by the increased initiatives by governments worldwide, the presence of favorable reimbursement policies, and the increasing prevalence of STDs.\nThe sexually transmitted disease (STD) testing market analysis includes product segment and geographic landscape.
  • This study identifies the increasing involvement of various organizations to create awareness about STDs as one of the prime reasons driving the sexually transmitted disease (STD) testing market growth during the next few years.
  • Also, advances that enable the rapid diagnosis of STDs and approval of drugs and strong drug pipeline will lead to sizable demand in the market.\n'

INVO Bioscience Announces Appointment of Rebecca Messina to the Board of Directors

Retrieved on: 
Monday, April 26, 2021
Women's health, Fertility medicine, Human reproduction, Infertility, Mycoplasma, Forward-looking statement, Vagina, Branches of biology, Articles

We are incredibly excited and honored that Rebecca was willing to help achieve our mission and we look forward to leveraging her broad experience in marketing and brand building within high growth industries as she joins the INVO Bioscience board of directors.

Key Points: 
  • We are incredibly excited and honored that Rebecca was willing to help achieve our mission and we look forward to leveraging her broad experience in marketing and brand building within high growth industries as she joins the INVO Bioscience board of directors.
  • Our solution, the INVO Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.
  • Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART).
  • Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov .

Under 30 and sexually active? It's a good idea to get tested for chlamydia and gonorrhea

Retrieved on: 
Monday, April 19, 2021
Medical specialties, Sexually transmitted diseases and infections, Infectious causes of cancer, Gonorrhea, Mycoplasma, Clinical medicine, Medicine, Chlamydia infections, Chlamydia, Pelvic inflammatory disease, Preventive healthcare, Infertility

Without treatment, these infections can lead to pelvic inflammatory disease, pain and possibly infertility.\n"If people are under 30 and sexually active, it\'s a good idea to get tested," says Dr. Ainsley Moore, a family physician and associate clinical professor, Department of Family Medicine, McMaster University, and chair of the Task Force chlamydia and gonorrhea working group.

Key Points: 
  • Without treatment, these infections can lead to pelvic inflammatory disease, pain and possibly infertility.\n"If people are under 30 and sexually active, it\'s a good idea to get tested," says Dr. Ainsley Moore, a family physician and associate clinical professor, Department of Family Medicine, McMaster University, and chair of the Task Force chlamydia and gonorrhea working group.
  • "Many people are asymptomatic and may not seek treatment so we\'re recommending opportunistic testing, that is, at any health care visit.
  • "\nThe guideline recommends that health care providers in Canada offer routine screening (testing) for chlamydia and gonorrhea to all sexually active patients under age 30 not known to belong to a high-risk group.
  • The task force\'s mandate is to develop and disseminate evidence-based clinical practice guidelines for primary and preventive care.\n'

Fertility Centers of Illinois Supports National Infertility Awareness Week

Retrieved on: 
Monday, April 12, 2021
Fertility medicine, Infertility, Mycoplasma, Women's health, Fertility awareness

b'CHICAGO, April 12, 2021 /PRNewswire-PRWeb/ -- Fertility Centers of Illinois (FCI) will recognize National Infertility Awareness Week (NIAW) on April 18-24 in the mission to build infertility awareness, shed stigma, and advocate for treatment access for a disease that affects one in eight couples.

Key Points: 
  • b'CHICAGO, April 12, 2021 /PRNewswire-PRWeb/ -- Fertility Centers of Illinois (FCI) will recognize National Infertility Awareness Week (NIAW) on April 18-24 in the mission to build infertility awareness, shed stigma, and advocate for treatment access for a disease that affects one in eight couples.
  • "We want people to get their questions answered by medical experts and encourage anyone having trouble to seek the help of a specialist.
  • Five attendees will win a free Fertility Awareness Checkup, valued at $90.
  • As the premier and largest fertility practice in the Midwest region, Fertility Centers of Illinois serves patients in the Chicagoland region, northern Indiana, and southern Wisconsin.

Autogenous Vaccines Market is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031)- Persistence Market Research

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Virology, Medicine, Clinical medicine, Autogenous vaccines, Vaccines, Vaccine, Antibiotic, Mycoplasma, Bacteria

Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.

Key Points: 
  • Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.
  • According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).
  • By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
  • Request for Sample PDF of Report: https://www.persistencemarketresearch.com/samples/29491
    "Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years," says an analyst of Persistence Market Research.

Autogenous Vaccines Market is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031)- Persistence Market Research

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Virology, Medicine, Clinical medicine, Autogenous vaccines, Vaccines, Vaccine, Antibiotic, Mycoplasma, Bacteria

Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.

Key Points: 
  • Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.
  • According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).
  • By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
  • Request for Sample PDF of Report: https://www.persistencemarketresearch.com/samples/29491
    "Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years," says an analyst of Persistence Market Research.